 Michael Falta
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Berylliosis | 14 | 2022 | 177 | 2.790 |
Why?
| | CD4-Positive T-Lymphocytes | 23 | 2021 | 965 | 2.260 |
Why?
| | Beryllium | 12 | 2022 | 146 | 2.070 |
Why?
| | HLA-DP beta-Chains | 10 | 2021 | 76 | 1.310 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 10 | 2017 | 310 | 1.090 |
Why?
| | Chemokine CCL3 | 1 | 2021 | 15 | 0.770 |
Why?
| | Chemokine CCL4 | 1 | 2021 | 21 | 0.770 |
Why?
| | Epitopes, T-Lymphocyte | 3 | 2021 | 170 | 0.670 |
Why?
| | Lung | 10 | 2022 | 3685 | 0.580 |
Why?
| | HLA-DP Antigens | 3 | 2010 | 32 | 0.510 |
Why?
| | Lymphocyte Activation | 7 | 2011 | 1056 | 0.440 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2016 | 630 | 0.410 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 9 | 2000 | 25 | 0.380 |
Why?
| | Sarcoidosis | 2 | 2022 | 133 | 0.350 |
Why?
| | T-Lymphocytes | 11 | 2016 | 1754 | 0.340 |
Why?
| | Genetic Predisposition to Disease | 5 | 2016 | 2209 | 0.310 |
Why?
| | Chronic Disease | 7 | 2022 | 1602 | 0.300 |
Why?
| | Antibody Affinity | 1 | 2005 | 52 | 0.250 |
Why?
| | Genes, MHC Class II | 1 | 2005 | 69 | 0.250 |
Why?
| | Hybridomas | 4 | 2021 | 230 | 0.250 |
Why?
| | Arthritis, Rheumatoid | 4 | 2005 | 1004 | 0.220 |
Why?
| | Aspergillus nidulans | 1 | 2021 | 5 | 0.200 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 2007 | 25 | 0.200 |
Why?
| | Mice | 9 | 2021 | 15073 | 0.190 |
Why?
| | Immunity, Innate | 2 | 2021 | 733 | 0.190 |
Why?
| | Mutation | 9 | 2000 | 3370 | 0.190 |
Why?
| | Azathioprine | 1 | 2000 | 50 | 0.180 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2017 | 609 | 0.170 |
Why?
| | Static Electricity | 2 | 2015 | 117 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 340 | 0.170 |
Why?
| | Lung Diseases | 3 | 2022 | 710 | 0.170 |
Why?
| | Antigens | 1 | 2021 | 322 | 0.170 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2793 | 0.170 |
Why?
| | Granuloma | 2 | 2022 | 85 | 0.160 |
Why?
| | Epitope Mapping | 2 | 2015 | 51 | 0.150 |
Why?
| | Mice, Transgenic | 4 | 2021 | 1970 | 0.150 |
Why?
| | Amino Acid Sequence | 6 | 2013 | 2000 | 0.150 |
Why?
| | Animals | 11 | 2021 | 32122 | 0.150 |
Why?
| | Humans | 40 | 2022 | 115901 | 0.140 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 58 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 1999 | 382 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2015 | 3583 | 0.130 |
Why?
| | Peptides | 3 | 2013 | 862 | 0.130 |
Why?
| | Amino Acid Motifs | 1 | 2015 | 198 | 0.120 |
Why?
| | Hypersensitivity | 2 | 2016 | 272 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2000 | 3258 | 0.110 |
Why?
| | Peptide Library | 1 | 2013 | 81 | 0.110 |
Why?
| | Clone Cells | 9 | 2005 | 247 | 0.110 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 44 | 0.100 |
Why?
| | Pulmonary Emphysema | 2 | 2006 | 318 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2012 | 196 | 0.100 |
Why?
| | Chagas Disease | 1 | 2012 | 34 | 0.100 |
Why?
| | Cell Line | 2 | 2016 | 2655 | 0.100 |
Why?
| | Autoantigens | 2 | 2005 | 399 | 0.100 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 12 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 358 | 0.100 |
Why?
| | Female | 19 | 2021 | 60081 | 0.090 |
Why?
| | Base Sequence | 6 | 2016 | 2120 | 0.090 |
Why?
| | Male | 17 | 2021 | 56127 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1442 | 0.090 |
Why?
| | Binding Sites | 1 | 2013 | 1183 | 0.090 |
Why?
| | Oligoclonal Bands | 2 | 2007 | 21 | 0.090 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 106 | 0.090 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 18 | 0.080 |
Why?
| | Synovial Fluid | 2 | 2000 | 57 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2007 | 686 | 0.080 |
Why?
| | Inflammation | 2 | 2022 | 2503 | 0.080 |
Why?
| | Autoimmunity | 1 | 2014 | 823 | 0.080 |
Why?
| | Crohn Disease | 1 | 2011 | 197 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2362 | 0.070 |
Why?
| | Adaptive Immunity | 2 | 2022 | 157 | 0.070 |
Why?
| | Poly I-C | 1 | 2006 | 52 | 0.070 |
Why?
| | Adult | 15 | 2021 | 30817 | 0.070 |
Why?
| | Interferon-beta | 1 | 2006 | 80 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 4 | 2011 | 399 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2006 | 187 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 1870 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 185 | 0.060 |
Why?
| | HLA-DR Antigens | 1 | 2005 | 220 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2005 | 189 | 0.060 |
Why?
| | Biomarkers | 2 | 2011 | 3474 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 222 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2021 | 3056 | 0.060 |
Why?
| | Enzyme-Linked Immunospot Assay | 2 | 2014 | 34 | 0.050 |
Why?
| | Drug Resistance | 2 | 2000 | 162 | 0.050 |
Why?
| | Middle Aged | 10 | 2021 | 27083 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 2021 | 782 | 0.050 |
Why?
| | Lactalbumin | 1 | 2001 | 2 | 0.050 |
Why?
| | Antigens, Fungal | 1 | 2021 | 28 | 0.050 |
Why?
| | Aged | 9 | 2017 | 19299 | 0.050 |
Why?
| | Forkhead Transcription Factors | 2 | 2014 | 170 | 0.050 |
Why?
| | HLA-DR3 Antigen | 1 | 2021 | 79 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2001 | 72 | 0.050 |
Why?
| | Muramidase | 1 | 2001 | 73 | 0.050 |
Why?
| | Crystallography, X-Ray | 2 | 2014 | 408 | 0.050 |
Why?
| | Fungal Proteins | 1 | 2021 | 124 | 0.050 |
Why?
| | Models, Molecular | 3 | 2014 | 1391 | 0.040 |
Why?
| | Histocompatibility Testing | 2 | 2012 | 115 | 0.040 |
Why?
| | HLA-DR4 Antigen | 1 | 2000 | 76 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2000 | 77 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 12 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2022 | 679 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2001 | 388 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2011 | 345 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 1999 | 522 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 3 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2001 | 538 | 0.040 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 99 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2001 | 703 | 0.040 |
Why?
| | Interferon-gamma | 2 | 2014 | 731 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1138 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 3 | 2012 | 503 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 44 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2000 | 666 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2000 | 1665 | 0.030 |
Why?
| | Adolescent | 5 | 2007 | 17956 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2000 | 675 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1001 | 0.030 |
Why?
| | Protein Structure, Secondary | 2 | 2010 | 327 | 0.030 |
Why?
| | Alleles | 2 | 2010 | 814 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1058 | 0.030 |
Why?
| | Protein Binding | 2 | 2011 | 1919 | 0.030 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 1994 | 13 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 917 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 445 | 0.030 |
Why?
| | Sister Chromatid Exchange | 1 | 1993 | 4 | 0.030 |
Why?
| | Sodium | 1 | 2014 | 182 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 400 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 1993 | 136 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2014 | 414 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2011 | 2598 | 0.030 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1994 | 224 | 0.030 |
Why?
| | Spleen | 1 | 2014 | 491 | 0.030 |
Why?
| | Disease Progression | 2 | 2011 | 2424 | 0.030 |
Why?
| | Radioimmunotherapy | 1 | 1991 | 10 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 342 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2012 | 273 | 0.020 |
Why?
| | Child | 3 | 2000 | 18557 | 0.020 |
Why?
| | Chromosome Deletion | 1 | 1991 | 95 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 78 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 353 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1993 | 263 | 0.020 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 1990 | 3 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 139 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 1994 | 521 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 66 | 0.020 |
Why?
| | CD3 Complex | 1 | 2010 | 92 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 451 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 174 | 0.020 |
Why?
| | DNA | 2 | 1993 | 1358 | 0.020 |
Why?
| | Prospective Studies | 1 | 2000 | 6267 | 0.020 |
Why?
| | Cells, Cultured | 3 | 2007 | 3916 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 605 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2010 | 213 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 25 | 0.020 |
Why?
| | Phosphorylation | 1 | 2011 | 1561 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2011 | 2581 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 60 | 0.020 |
Why?
| | Proteinuria | 1 | 2006 | 78 | 0.020 |
Why?
| | Lupus Nephritis | 1 | 2006 | 52 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1817 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2006 | 102 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 262 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1044 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1262 | 0.010 |
Why?
| | Antigens, CD | 2 | 2000 | 442 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 3342 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2196 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1843 | 0.010 |
Why?
| | Fatty Acid-Binding Protein 7 | 1 | 2001 | 3 | 0.010 |
Why?
| | Camelids, New World | 1 | 2001 | 5 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4122 | 0.010 |
Why?
| | Blotting, Southern | 2 | 1991 | 66 | 0.010 |
Why?
| | Statistics as Topic | 2 | 1993 | 299 | 0.010 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2001 | 63 | 0.010 |
Why?
| | Solvents | 1 | 2001 | 109 | 0.010 |
Why?
| | Chickens | 1 | 2001 | 183 | 0.010 |
Why?
| | Perforin | 1 | 2000 | 17 | 0.010 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2000 | 14 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2000 | 46 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2001 | 513 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2112 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2000 | 156 | 0.010 |
Why?
| | Ligands | 1 | 2001 | 568 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1990 | 5090 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1693 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1998 | 35 | 0.010 |
Why?
| | Gene Frequency | 2 | 1990 | 507 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 590 | 0.010 |
Why?
| | Cartilage | 1 | 2000 | 182 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2000 | 302 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2000 | 312 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 429 | 0.010 |
Why?
| | Collagen | 1 | 2000 | 415 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 887 | 0.010 |
Why?
| | Thioguanine | 1 | 1994 | 19 | 0.010 |
Why?
| | Lymphoma, T-Cell | 1 | 1994 | 21 | 0.010 |
Why?
| | Hepatitis | 1 | 1994 | 45 | 0.010 |
Why?
| | Infant | 1 | 2007 | 8002 | 0.010 |
Why?
| | Signal Transduction | 1 | 2006 | 4526 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 9177 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 745 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5035 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1993 | 182 | 0.010 |
Why?
| | Cell Differentiation | 1 | 1998 | 1706 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 395 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1991 | 156 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 1993 | 6438 | 0.010 |
Why?
| | Karyotyping | 1 | 1990 | 102 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 1990 | 72 | 0.010 |
Why?
| | Genes | 1 | 1990 | 223 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 1990 | 135 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 1994 | 407 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1990 | 151 | 0.010 |
Why?
| | Heterozygote | 1 | 1990 | 254 | 0.010 |
Why?
| | Mutagenicity Tests | 1 | 1989 | 9 | 0.010 |
Why?
| | Fetal Blood | 1 | 1990 | 268 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 1743 | 0.000 |
Why?
| | Immunotherapy | 1 | 1990 | 480 | 0.000 |
Why?
| | Age Factors | 1 | 1993 | 2915 | 0.000 |
Why?
| | Smoking | 1 | 1993 | 1468 | 0.000 |
Why?
| | Phenotype | 1 | 1990 | 2859 | 0.000 |
Why?
| | Risk Factors | 1 | 1993 | 8714 | 0.000 |
Why?
|
|
Falta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|